Kwangdong Phar Cash Flow Conversion Efficiency
Kwangdong Phar cash flow conversion efficiency. Based on the latest financial reports, Kwangdong Phar (009290) has a cash flow conversion efficiency ratio of -0.018x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-12.75 Billion ≈ $-8.64 Million USD) by net assets (₩705.01 Billion ≈ $477.77 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Kwangdong Phar (2011–2025)
Cash flow conversion efficiency of Kwangdong Phar from 2011 to 2025. This chart illustrates how Kwangdong Phar's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Kwangdong Phar (009290) share price today for real-time trading data and today's change.
Kwangdong Phar Cash Flow Conversion Ratio Explained
Kwangdong Phar cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Kwangdong Phar Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kwangdong Phar ranked by their cash flow conversion efficiency. Also see market cap of Kwangdong Phar for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ehang Holdings Ltd
NASDAQ:EH
|
-0.157x |
|
Shenzhen Jianyi Decoration Group Co Ltd
SHE:002789
|
0.236x |
|
Valid Soluções S.A
SA:VLID3
|
0.074x |
|
Oryzon Genomics SA
MC:ORY
|
-0.020x |
|
SIGA Technologies Inc
NASDAQ:SIGA
|
0.000x |
|
Jeju Bank
KO:006220
|
0.474x |
|
Celik Halat ve Tel Sanayi AS
IS:CELHA
|
-0.030x |
|
Xingguang Agricultural Mach
SHG:603789
|
-0.127x |
Annual Cash Flow Conversion Efficiency for Kwangdong Phar (2011–2025)
The table below shows the annual cash flow conversion efficiency of Kwangdong Phar from 2011 to 2025. Review 009290 cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩711.80 Billion ≈ $482.37 Million |
₩82.34 Billion ≈ $55.80 Million |
0.116x | +688.50% |
| 2024-12-31 | ₩618.27 Billion ≈ $418.99 Million |
₩-12.15 Billion ≈ $-8.24 Million |
-0.020x | +1.46% |
| 2023-12-31 | ₩588.05 Billion ≈ $398.51 Million |
₩-11.73 Billion ≈ $-7.95 Million |
-0.020x | -117.37% |
| 2022-12-31 | ₩547.05 Billion ≈ $370.73 Million |
₩62.82 Billion ≈ $42.57 Million |
0.115x | +10.21% |
| 2021-12-31 | ₩527.24 Billion ≈ $357.31 Million |
₩54.94 Billion ≈ $37.23 Million |
0.104x | +129.22% |
| 2020-12-31 | ₩502.18 Billion ≈ $340.32 Million |
₩22.83 Billion ≈ $15.47 Million |
0.045x | -30.54% |
| 2019-12-31 | ₩447.46 Billion ≈ $303.24 Million |
₩29.29 Billion ≈ $19.85 Million |
0.065x | -46.89% |
| 2018-12-31 | ₩430.84 Billion ≈ $291.97 Million |
₩53.10 Billion ≈ $35.98 Million |
0.123x | +118.65% |
| 2017-12-31 | ₩416.30 Billion ≈ $282.12 Million |
₩23.46 Billion ≈ $15.90 Million |
0.056x | -21.78% |
| 2016-12-31 | ₩399.68 Billion ≈ $270.86 Million |
₩28.80 Billion ≈ $19.52 Million |
0.072x | -33.84% |
| 2015-12-31 | ₩377.73 Billion ≈ $255.98 Million |
₩41.14 Billion ≈ $27.88 Million |
0.109x | +4.55% |
| 2014-12-31 | ₩314.40 Billion ≈ $213.06 Million |
₩32.75 Billion ≈ $22.19 Million |
0.104x | -11.92% |
| 2013-12-31 | ₩290.82 Billion ≈ $197.09 Million |
₩34.39 Billion ≈ $23.31 Million |
0.118x | +33.16% |
| 2012-12-31 | ₩267.27 Billion ≈ $181.13 Million |
₩23.74 Billion ≈ $16.09 Million |
0.089x | -19.93% |
| 2011-12-31 | ₩249.52 Billion ≈ $169.09 Million |
₩27.68 Billion ≈ $18.76 Million |
0.111x | -- |
About Kwangdong Phar
Kwang Dong Pharmaceutical Co., Ltd. operates as a human healthcare provider in South Korea. It develops and sells OTC drugs in the areas of ophthalmic, mineral preparations, nutritious tonics, antipyretic, analgesic, anti inflammatory agents, circulating system, and vitamins; and ETC drugs in the areas of anti-malignant-tumor agent, obesity drug, appetite suppressant, antipyretic, analgesic, anti… Read more